Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176731 · ClinicalTrials.gov registry record · NA
Prepivotal Omnipod Horizon™ Automated Glucose Control System
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT04176731 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 36 participants.
The verdict
NCT04176731, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and outpatient setting.
Interventions
- DEVICE Omnipod Horizon™ Automated Glucose Control System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-12-15 |
| Est. Completion | 2020-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176731
The ClinicalTrials.gov registry entry for NCT04176731 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insulet Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omnipod Horizon™ Automated Glucose Control System is the first listed.
NCT04176731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04176731 about?
NCT04176731 is a clinical study titled "Prepivotal Omnipod Horizon™ Automated Glucose Control System". Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and outpatient setting.
What is the current status of trial NCT04176731?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2019-12-15. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT04176731?
The interventions under investigation include: Omnipod Horizon™ Automated Glucose Control System (DEVICE).
Who is sponsoring clinical trial NCT04176731?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.